Economic Observation Network Johnson&Johnson (JNJ) bevacizumab has received accelerated FDA approval for the treatment of recurrent/metastatic head and neck squamous cell carcinoma after platinum based chemotherapy and PD - (L) 1 treatment failure. Clinical data shows significant superiority over traditional treatment regimens, with outstanding ease of administration.
Progress of drug approval
The FDA is accelerating its approval for the use of bevacizumab in recurrent/metastatic head and neck squamous cell carcinoma after platinum based chemotherapy and PD - (L) 1 treatment failure. This is the first dual target therapy approved for this indication and also the first time that bevacizumab has emerged from lung cancer. Key data: Objective remission rate is 42%, of which 15% achieve complete remission, and 56% of remission patients have a duration of ≥ 6 months; However, the traditional treatment plan for this type of posterior line patients rarely has a remission rate exceeding 24%, and the five-year survival rate is only about 15%
The above content is based on publicly available information and does not constitute investment advice.